rs137852564
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 14P and 1B. PM1PM2PM5PP5_Very_StrongBP4
The NM_000044.6(AR):c.2599G>A(p.Val867Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000911 in 1,098,026 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V867E) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000044.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AR | NM_000044.6 | c.2599G>A | p.Val867Met | missense_variant | 7/8 | ENST00000374690.9 | NP_000035.2 | |
AR | NM_001011645.3 | c.1003G>A | p.Val335Met | missense_variant | 8/9 | NP_001011645.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AR | ENST00000374690.9 | c.2599G>A | p.Val867Met | missense_variant | 7/8 | 1 | NM_000044.6 | ENSP00000363822 | P1 | |
AR | ENST00000396044.8 | c.2174-710G>A | intron_variant | 1 | ENSP00000379359 | |||||
AR | ENST00000396043.4 | c.*947G>A | 3_prime_UTR_variant, NMD_transcript_variant | 8/9 | 1 | ENSP00000379358 | ||||
AR | ENST00000612452.5 | c.2599G>A | p.Val867Met | missense_variant, NMD_transcript_variant | 7/9 | 5 | ENSP00000484033 |
Frequencies
GnomAD3 genomes Cov.: 22
GnomAD4 exome AF: 9.11e-7 AC: 1AN: 1098026Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 363436
GnomAD4 genome Cov.: 22
ClinVar
Submissions by phenotype
Androgen resistance syndrome Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 1989 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics | Feb 18, 2020 | A homozygous missense variation in exon 7 of the AR gene that results in amino acid substitution of methionine for valine at codon 867 was detected. The observed variant c.2599G>A has not been reported in the 1000 genomes and ExAC databases. The variant lies in the ligand-binding domain of nuclear hormone receptor domain of the AR protein and has previously been reported as p.Val866Met in patients affected with androgen insensitivity (Lubahn et al. 1989). The in silico prediction of the variant are probably damaging by PolyPhen-2 (HumDiv) and damaging by LRT. The reference codon is conserved across species. In summary, the variant meets our criteria to be classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Molecular Genetics Laboratory, Johns Hopkins All Children's Hospital | Aug 05, 2016 | - - |
Androgen resistance syndrome;C1839259:Kennedy disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 11, 2020 | This sequence change replaces valine with methionine at codon 867 of the AR protein (p.Val867Met). The valine residue is moderately conserved and there is a small physicochemical difference between valine and methionine. This variant is not present in population databases (ExAC no frequency). For these reasons, this variant has been classified as Pathogenic. This variant is located in the ligand binding domain of the androgen receptor(AR) protein and experimental evidence using genital fibroblast cultures shows this variant has reduced dihydrotestosterone(DHT)-dependent, AR-induced transcriptional activation (PMID: 27583472). This variant has been reported in individuals and families affected with partial androgen insensitivity syndrome (PMID: 2594783, 26806084, 26688387). This variant is also known as p.Val866Met. ClinVar contains an entry for this variant (Variation ID: 9806). - |
Androgen resistance syndrome;C0268301:Partial androgen insensitivity syndrome;C0376358:Malignant tumor of prostate;C1839259:Kennedy disease;C2678098:Hypospadias 1, X-linked Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
AR-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 19, 2023 | The AR c.2599G>A variant is predicted to result in the amino acid substitution p.Val867Met. This variant, also known as p.Val866Met, has been reported in multiple individuals with androgen insensitivity syndrome (Lubahn et al 1989. PubMed ID: 2594783; Abilash et al. 2016. PubMed ID: 26688387; Li L et al 2017. PubMed ID: 26806084; Suppl. Table 1, Eggers S et al 2016. PubMed ID: 27899157). This variant lies in the ligand-binding domain of the androgen receptor protein. Functional studies show that this variant reduces dihydrotestosterone (DHT)-dependent, AR-induced transcriptional activation (Horing et al. 2016. PubMed ID: 27583472). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at